New START for Kumar Muthalagappan
Entrepreneur and philanthropist will assist South Texas Accelerated Research Therapeutics (START) in its quest to expand globally
Clinical Scorecard: New START for Kumar Muthalagappan
At a Glance
| Category | Detail |
|---|
| Condition | Cancer |
| Key Mechanisms | Accelerating the development of anti-cancer drugs |
| Target Population | Patients with cancer |
| Care Setting | Oncology research organization |
Key Highlights
- Kumar Muthalagappan appointed to assist START in global expansion
- START has 10 existing sites globally, including in Europe
- Focus on improving quality of life and survival rates for cancer patients
- Muthalagappan has extensive experience in clinical research and oncology
- Previous roles include CEO of MeDiNova and founder of Oncacare
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Cancer patients seeking novel treatments
Focus on clinical trials for anti-cancer drug development
Clinical Best Practices
- Leverage global networks to enhance clinical trial opportunities
- Integrate patient data collection for improved research outcomes
- Collaborate with oncologists and pharmaceutical organizations
Related Resources & Content
